NEW YORK (GenomeWeb News) – Investment firm ISI Group on Wednesday downgraded shares of Hologic, saying the company's new management will need time to turn the business around.

ISI downgraded Hologic's shares to Buy from a previous Strong Buy rating, but maintained earlier EPS estimates of $1.35 for Fiscal Year 2014; $1.55 for FY 2015; and $1.75 for FY 2016.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.